{"id":534053,"date":"2025-12-22T00:00:00","date_gmt":"2025-12-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0054-2025-biopharma-chronic-urticaria-current-treatment-treatment-algorithms-claims-data-analysis-chronic\/"},"modified":"2026-03-31T10:23:44","modified_gmt":"2026-03-31T10:23:44","slug":"algoim0054-2025-biopharma-chronic-urticaria-current-treatment-treatment-algorithms-claims-data-analysis-chronic","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0054-2025-biopharma-chronic-urticaria-current-treatment-treatment-algorithms-claims-data-analysis-chronic\/","title":{"rendered":"Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US)"},"content":{"rendered":"
\n

Chronic inducible urticaria (CIndU<\/abbr>) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU<\/abbr> seems to be more resistant than chronic spontaneous urticaria (CSU<\/abbr>) to standard doses of antihistamines, although claims data analysis reveals positive uptake trends among both first- and second-generation antihistamines such as Vistaril and Zyrtec, respectively. Vistaril, Benadryl, Zyrtec, and montelukast are also key drugs in the CIndU<\/abbr> therapy market and are often used in combination therapy, despite the removal of leukotriene receptor antagonists (e.g., montelukast) from current treatment guidelines. Although no biologics have been approved for CIndU<\/abbr>, some biologics (e.g., TNF<\/abbr> inhibitors, Roche \/ Novartis\u2019s Xolair, Sanofi \/ Regeneron\u2019s Dupixent) are used off-label for the indication, mainly as later-line therapy. Thus, more-effective drugs targeting CIndU<\/abbr> have good potential for uptake.<\/p>\n<\/div>\n

\n

Questions answered<\/strong><\/p>\n<\/div>\n

\n
    \n
  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CIndU<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CIndU<\/abbr> patients?<\/li>\n
  • How have Xolair, TNF<\/abbr>-alpha inhibitors, and Dupixent been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n
  • What percentage of CIndU<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n
  • What percentage of CIndU<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n
  • What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<\/div>\n
    \n

    Product description<\/strong><\/p>\n<\/div>\n

    \n

    Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<\/div>\n

    \n
      \n
    • Understand patient flow between lines of therapy.<\/li>\n<\/ul>\n<\/div>\n
      \n
        \n
      • Evaluate your brand share against competitors.<\/li>\n<\/ul>\n<\/div>\n
        \n
          \n
        • Accurately assess your source of business.<\/li>\n<\/ul>\n<\/div>\n
          \n
            \n
          • Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n
            \n

            Geography: <\/b>United States<\/p>\n

            \n

            Real-world data:<\/strong> Longitudinal patient-level claims data analysis<\/p>\n

            \n

            Key drugs covered:<\/strong> Allegra, Zyrtec, Xolair, Benadryl, montelukast, Vistaril, Silenor, Humira, Dupixent<\/p>\n

            \n

            Key analyses:<\/strong> Brand \/ therapy usage across longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flow charts<\/p>\n

            \n

            Key feature:<\/strong> Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n

            Product enhancement<\/strong><\/p>\n

            Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"template":"","class_list":["post-534053","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-urticaria","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/534053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/534053\/revisions"}],"predecessor-version":[{"id":571904,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/534053\/revisions\/571904"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=534053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}